These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 12481149

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
    Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J.
    Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration.
    Toto RD, Pichette V, Navarro J, Brenner R, Carroll W, Liu W, Roger S.
    Am J Nephrol; 2004 Feb; 24(4):453-60. PubMed ID: 15331889
    [Abstract] [Full Text] [Related]

  • 6. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
    Mahajan S, Boulton H, Gokal R.
    J Nephrol; 2004 Feb; 17(5):687-92. PubMed ID: 15593036
    [Abstract] [Full Text] [Related]

  • 7. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R, Bommer J, Braun J, Haag-Weber M, Gill C, Wagner J, Wagener T, German Aranesp Study Group.
    Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
    [Abstract] [Full Text] [Related]

  • 8. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease.
    Ling B, Walczyk M, Agarwal A, Carroll W, Liu W, Brenner R.
    Clin Nephrol; 2005 May; 63(5):327-34. PubMed ID: 15909591
    [Abstract] [Full Text] [Related]

  • 9. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease.
    Agarwal A, Silver MR, Walczyk M, Liu W, Audhya P.
    J Am Med Dir Assoc; 2007 Feb; 8(2):83-90. PubMed ID: 17289537
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
    Mirtsching B, Charu V, Vadhan-Raj S, Colowick AB, Rossi G, Tomita D, McGuire WP.
    Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):31-6. PubMed ID: 12435171
    [Abstract] [Full Text] [Related]

  • 12. Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease.
    Hertel JE, Locay HR, Scarlata DS, Prathikanti R, Audhya PK.
    Mayo Clin Proc; 2006 Sep; 81(9):1188-94. PubMed ID: 16970215
    [Abstract] [Full Text] [Related]

  • 13. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
    Kessler M, Hannedouche T, Fitte H, Cayotte JL, Urena P, Réglier JC, Groupe de l'étude NESP 20000117.
    Nephrol Ther; 2006 Sep; 2(4):191-9. PubMed ID: 16966064
    [Abstract] [Full Text] [Related]

  • 14. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M, García Hernández MA, Navarro MJ, Pérez Silva F, Cacho M, De Gracia MC.
    Nefrologia; 2004 Sep; 24(1):54-9. PubMed ID: 15083958
    [Abstract] [Full Text] [Related]

  • 15. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis.
    Macdougall IC, Matcham J, Gray SJ, NESP 960245/246 Study Group.
    Nephrol Dial Transplant; 2003 Mar; 18(3):576-81. PubMed ID: 12584282
    [Abstract] [Full Text] [Related]

  • 16. Subcutaneous administration of darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals in peritoneal dialysis patients.
    Fang YW, Chang CH.
    Perit Dial Int; 2009 Mar; 29(2):199-203. PubMed ID: 19293358
    [Abstract] [Full Text] [Related]

  • 17. Effect of darbepoetin alfa administered once monthly on maintaining hemoglobin levels in older patients with chronic kidney disease.
    Silver MR, Agarwal A, Krause M, Lei L, Stehman-Breen C.
    Am J Geriatr Pharmacother; 2008 Jun; 6(2):49-60. PubMed ID: 18675764
    [Abstract] [Full Text] [Related]

  • 18. Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents.
    Silver MR, Geronemus R, Krause M, Chen CY, Kewalramani R, Stehman-Breen C.
    Curr Med Res Opin; 2009 Jan; 25(1):123-31. PubMed ID: 19210145
    [Abstract] [Full Text] [Related]

  • 19. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients.
    Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ.
    Nephrol Dial Transplant; 2004 Apr; 19(4):898-903. PubMed ID: 15031347
    [Abstract] [Full Text] [Related]

  • 20. Darbepoetin alfa: a novel erythropoiesis-stimulating protein.
    Cases A.
    Drugs Today (Barc); 2003 Jul; 39(7):477-95. PubMed ID: 12973399
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.